Skip to Main content Skip to Navigation
Journal articles

Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT

Annalisa Paviglianiti 1, 2 Myriam Labopin 1, 2 Didier Blaise 3, 4 Gerard Socié 5 Claude Eric Bulabois 6, 7 Bruno Lioure 8 Patrice Ceballos 9 Igor Wolfgang Blau 10 Gaelle Guillerm 11 Johan Maertens 12 Patrice Chevallier 13 Anne Huynh 14 Pascal Turlure 15 Eric Deconinck 16 Edouard Forcade 17 Arnon Nagler 18 Mohamad Mohty 1, 2
1 CHU Saint-Antoine [AP-HP]
2 CRSA - Centre de Recherche Saint-Antoine
3 Institut Paoli-Calmettes
4 CRCM - Centre de Recherche en Cancérologie de Marseille
5 AP-HP - Hopital Saint-Louis [AP-HP]
6 CHU - Centre Hospitalier Universitaire [Grenoble]
7 UGA - Université Grenoble Alpes
8 Hôpital de Hautepierre [Strasbourg]
9 CHU - Hôpital Lapeyronie [Montpellier]
10 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
11 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
12 University Hospital Gasthuisberg
13 CHU Nantes - Centre hospitalier universitaire de Nantes
14 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
15 CHU Limoges
16 Hôpital JeanMinjoz
17 CHU Bordeaux [Bordeaux]
18 Tel Aviv University [Tel Aviv]
Abstract : The association of Cyclosporine A (CsA) and mycophenolate mofetil (MMF) has increased in the setting of reduced intensity conditioning (RIC). Nevertheless, the use of CsA or CsA+MMF has not been reported in a large and uniform cohort. We analyzed 497 patients with acute myeloid leukemia in complete remission (CR) who underwent matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT). All patients received a fludarabine busulfan RIC regimen and anti-thymocyte globulin (ATG) with either CsA alone or in combination with MMF. The cumulative incidence (CI) of grade II-IV acute GvHD was 27% (95% CI 21-33%) for CsA and 33% (95% CI 27-38%) for CsA+MMF (p = 0.25). The 2-year CI of chronic GvHD was 38% (95% CI 31-45%) and 33% (95% CI 28-39%) for the CsA and the CsA+MMF group, respectively (p = 0.26). On multivariate analysis, no statistically significant differences with respect to relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS), acute and chronic GvHD were found between the two groups, also when conducting a subgroup analysis in peripheral blood stem cells (PBSC) recipients. Our results support the importance of randomized trial to identify patients who could benefit from the addition of MMF in MUD HSCT.
Document type :
Journal articles
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-03623664
Contributor : Jacques A Nunes Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 6:20:19 PM
Last modification on : Friday, April 1, 2022 - 3:58:04 AM

Links full text

openaccess

Identifiers

Collections

UNIV-AMU | CRCM | CNRS | INSERM | UNIV-TLSE3 | U938 | SORBONNE-UNIVERSITE | SU-MEDECINE | SU-TI | UGA

Citation

Annalisa Paviglianiti, Myriam Labopin, Didier Blaise, Gerard Socié, Claude Eric Bulabois, et al.. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. Bone Marrow Transplantation, Nature Publishing Group, 2021, 56 (5), pp.1077-1085. ⟨10.1038/s41409-020-01155-z⟩. ⟨hal-03623664⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

6